Observational studyBMC geriatrics2026
Single-center experience with hemoptysis in geriatric patients.
Observational study in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemoptysis is a serious clinical condition, particularly in geriatric patients, due to age-related physiological changes and multiple comorbidities. This study aims to evaluate the etiologies, interventional management strategies, and outcomes of hemoptysis in patients aged 65 years and older.
methodsThis single-center, retrospective observational study analyzed 1383 geriatric patients who presented with hemoptysis between 2012 and 2022. Demographic characteristics, comorbidities, bleeding severity, biochemical parameters, and interventional procedures including fiberoptic bronchoscopy, rigid bronchoscopy, and bronchial artery embolization were evaluated.
resultsThe mean age of the patients was 72.66 ± 6.04 years, and 76.9% were male. Lung cancer was identified as the most common cause of hemoptysis. Minimal bleeding was the most frequent presentation (49.5%). No statistically significant relationship was found between age, bleeding volume, or mortality. Interventional procedures were performed at similar rates across all age groups, and the success and safety of bronchoscopic and embolization interventions were comparable to those reported in younger populations. Biochemical parameters showed no correlation with bleeding severity or mortality.
conclusionsAge alone is not a determinant of hemoptysis severity or mortality. Interventional pulmonary procedures are safe and effective in geriatric patients. Biochemical parameters do not predict hemoptysis outcomes. These findings support an individualized, evidence-based approach to hemoptysis management in elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.